XM does not provide services to residents of the United States of America.
A
A

Aviva

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UK Labour's win: a burden for Diversified Financials and Insurance, a relief for Utilities

LIVE MARKETS-UK Labour's win: a burden for Diversified Financials and Insurance, a relief for Utilities STOXX 600 up 0.5% FTSE 100 +0.3%, FTSE 250 +1% Labour wins big majority Payrolls in focus S&P futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com UK LABOUR'S WIN: A BURDEN FOR DIVERSIFIED FINANCIALS AND INSURANCE, A RELIEF FOR UTILITIES With a centre-left Labour winn
A
A
B
H
S
D
N
E
F
U
G

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

Smith & Nephew shares soar as activist Cevian builds stake

UPDATE 3-Smith & Nephew shares surge on activist Cevian building stake Cevian's 5% stake to make it no.2 shareholder in S+N S+N shares rise to top of FTSE 100 Cevian sees potential by improving operating performance S+N says will continue talks with Cevian Adds analyst quote in paragraphs 10-11 By Yadarisa Shabong July 4 (Reuters) - Shares in Smith & Nephew SN.L rose 7% to the top of the FTSE 100 index on Thursday after activist investor Cevian Capital disclosed a 5% stake in the British medical
A
B
P
U

Smith & Nephew shares soar as activist Cevian discloses stake

Smith & Nephew shares soar as activist Cevian discloses stake July 4 (Reuters) - Shares in Smith & Nephew SN.L rose nearly 7% on Thursday after activist investor Cevian Capital disclosed a 5% stake in the British medical equipment maker, a filing showed. Smith & Nephew, which makes orthopaedic implants and prosthetics, wound dressings, and other surgical materials, has lost more than 50% of its stock value since February 2020, just before the pandemic lockdowns.
A
A
B
U
U

Aviva Completes 300 Mln Stg Share Buyback Programme

BRIEF-Aviva Completes 300 Mln Stg Share Buyback Programme July 1 (Reuters) - Aviva PLC AV.L : COMPLETION OF £300M SHARE BUYBACK PROGRAMME COMPLETES £300M SHARE BUYBACK PROGRAMME Source text for Eikon: ID:nRSA4792Ua Further company coverage: AV.L
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.